Top Markets
Coin of the day
Adagio Therapeutics, Inc. Adagio Therapeutics, Inc.

Adagio Therapeutics, Inc.

ADGI
株式のランク #16435
Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily... Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical firm, primarily focused on the discovery, development, and subsequent commercialization of antibody-based therapeutics designed to combat infectious diseases across the United States. Its most advanced product candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical trials. This antibody is being evaluated for both the treatment and prevention of coronavirus disease. Adagio Therapeutics also engages in strategic collaborations. It partners with Adimab, LLC to facilitate the discovery and optimization of novel proprietary antibodies. Furthermore, the company works with the Scripps Research Institute on research initiatives aimed at identifying vaccine candidates that could prevent, diagnose, or treat influenza and beta coronaviruses. Founded in 2020, Adagio Therapeutics maintains its headquarters in Waltham, Massachusetts.
株価
$4.64
最終同期: 2022-09-12
時価総額
$293.43M
変化(1日)
0.87%
変化(1年)
0.00%
US
取引 Adagio Therapeutics, Inc. (ADGI)

カテゴリー

Adagio Therapeutics, Inc.(ADGI)の株式分割履歴
Adagio Therapeutics, Inc.株(シンボル:ADGI)は合計で0回の株式分割を実施しました。
最新の株式分割はSep 02, 2026に行われました。
Sep 02, 2026より前に購入されたADGI株は、現在0ADGI株に相当します。
株式分割一覧
株式分割 分割比率 累積分割比率
提供された日付のデータは十分ではありません。
類似企業または競合他社の株式分割
企業 株式分割の回数 累積分割比率
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH